<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00066417</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000315900</org_study_id>
    <secondary_id>NHLBI-03-H-0209</secondary_id>
    <nct_id>NCT00066417</nct_id>
    <nct_alias>NCT00062725</nct_alias>
  </id_info>
  <brief_title>Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia</brief_title>
  <official_title>Pilot Study Of T-Cell-Depleted Peripheral Blood Stem Cell Transplantation From Partially Matched Related Donors For Patients With High-Risk Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell&#xD;
      transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's&#xD;
      immune system from rejecting the donor's stem cells. When the stem cells from a related&#xD;
      donor, that do not exactly match the patient's blood, are infused into the patient they may&#xD;
      help the patient's bone marrow make stem cells, red blood cells, white blood cells, and&#xD;
      platelets.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well peripheral stem cell transplant works in&#xD;
      treating patients with high-risk leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety of a preparative regimen comprising total body irradiation,&#xD;
           cyclophosphamide, thiotepa, and fludarabine, but without anti-thymocyte globulin, in&#xD;
           patients with high-risk leukemia treated with peripheral blood stem cell transplantation&#xD;
           from partially matched related donors.&#xD;
&#xD;
        -  Determine the incidence of graft failure, acute graft-versus-host disease (GVHD), and&#xD;
           treatment-related mortality in patients treated with this regimen.&#xD;
&#xD;
        -  Determine rates of chronic GVHD and relapse in patients treated with this regimen.&#xD;
&#xD;
        -  Determine disease-free and overall survival in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a pilot study.&#xD;
&#xD;
      Patients receive a preparative regimen comprising total lymphoid irradiation once daily on&#xD;
      days -13 to -11; cyclophosphamide IV over 1 hour on days -8 and -7; thiotepa IV over 4 hours&#xD;
      every 12 hours on day -6; fludarabine IV over 30 minutes on days -5 to -1; and total body&#xD;
      irradiation once on day -1. Patients also receive cyclosporine IV over 12 hours on days -8 to&#xD;
      -1 and methylprednisolone IV twice daily on days -3 and -2. Patients receive CD34-enriched&#xD;
      T-cell-depleted allogeneic stem cell infusion on day 0.&#xD;
&#xD;
      Patients with disease progression or uncontrolled infection but without grade II or greater&#xD;
      graft-versus-host disease may receive up to 3 donor lymphocyte infusions at least 4 weeks&#xD;
      apart until disease regression.&#xD;
&#xD;
      Patients are followed at least weekly until day 100 and then at 6, 12, 18, 24, 36, and 48&#xD;
      months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20-51 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Trial was withdrawn for drug availability issues.&#xD;
  </why_stopped>
  <completion_date type="Actual">January 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of graft failure 100 days post-transplant</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of acute and chronic graft-vs-host disease100 days post-transplant</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Transplant-related mortality 100 days post-transplant</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-free survival 100 days post-transplant</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival 100 days post-transplant</measure>
  </primary_outcome>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic/Myeloproliferative Diseases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>therapeutic allogeneic lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thiotepa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biological therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bone marrow ablation with stem cell support</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>leukocyte therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>non-specific immune-modulator therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood lymphocyte therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of 1 of the following:&#xD;
&#xD;
               -  High-risk myelodysplastic syndromes (MDS), meeting 1 of the following criteria:&#xD;
&#xD;
                    -  Transformation to acute leukemia defined by at least 15% blasts&#xD;
&#xD;
                    -  Secondary to prior treatment with chemotherapy and/or radiotherapy&#xD;
&#xD;
                    -  Presence of complex cytogenetics (at least 3 karyotypic abnormalities)&#xD;
&#xD;
                    -  Monosomy or deletion of chromosome 7&#xD;
&#xD;
               -  Acute myeloid leukemia (AML), meeting 1 of the following criteria :&#xD;
&#xD;
                    -  High-risk AML in first remission and meeting 1 of the following criteria:&#xD;
&#xD;
                         -  At least 3 karyotypic abnormalities&#xD;
&#xD;
                         -  Monosomy or deletion of chromosome 5 or 7 = 11q23 chromosomal&#xD;
                            abnormality&#xD;
&#xD;
                         -  Prior diagnosis of MDS&#xD;
&#xD;
                         -  Received prior radiotherapy or chemotherapy&#xD;
&#xD;
                    -  In second or subsequent remission&#xD;
&#xD;
                    -  Primary induction failure or partial remission&#xD;
&#xD;
                    -  Untested or sensitive relapse&#xD;
&#xD;
               -  Chronic myelogenous leukemia, meeting 1 of the following criteria:&#xD;
&#xD;
                    -  Blast crisis&#xD;
&#xD;
                    -  Accelerated phase disease that has failed prior treatment with imatinib&#xD;
                       mesylate, defined as a failure to achieve hematologic response after 3&#xD;
                       months of standard dose (600 mg/day) therapy or disease progression on&#xD;
                       therapy&#xD;
&#xD;
               -  Myeloproliferative disease&#xD;
&#xD;
                    -  The following diagnoses are eligible:&#xD;
&#xD;
                         -  Agnogenic myeloid metaplasia&#xD;
&#xD;
                         -  Essential thrombocythemia&#xD;
&#xD;
                         -  Polycythemia vera&#xD;
&#xD;
                    -  Must have evidence of transformation to acute leukemia&#xD;
&#xD;
               -  Acute lymphocytic leukemia (ALL), meeting 1 of the following criteria:&#xD;
&#xD;
                    -  High-risk ALL in first remission defined by 1 of the following:&#xD;
&#xD;
                         -  t(9;22) or 11q23 chromosomal abnormality&#xD;
&#xD;
                         -  Complete response at least 4 weeks after induction therapy OR requiring&#xD;
                            at least 2 induction regimens&#xD;
&#xD;
                    -  Second or subsequent remission&#xD;
&#xD;
          -  No relapsed leukemia refractory to appropriate salvage therapy&#xD;
&#xD;
          -  Availability of an HLA-mismatched family donor&#xD;
&#xD;
               -  Donor age 75 or under&#xD;
&#xD;
          -  No better donor alternative (i.e., HLA-matched related or unrelated stem cell donor)&#xD;
             is available&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  10 to 50&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 4 mg/dL&#xD;
&#xD;
          -  Transaminases no greater than 3 times upper limit of normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  LVEF at least 40%&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  DLCO at least 65% of predicted&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other prior malignancy except basal cell or squamous cell skin cancer or a remote&#xD;
             history of cancer now considered cured&#xD;
&#xD;
          -  No major organ dysfunction that would preclude transplantation&#xD;
&#xD;
          -  No major anticipated illness or organ failure that would preclude transplantation&#xD;
&#xD;
          -  No severe psychiatric illness or mental deficiency that would preclude giving informed&#xD;
             consent or complying with study&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bipin N. Savani, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Heart, Lung, and Blood Institute (NHLBI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NIH - Warren Grant Magnuson Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2006</verification_date>
  <study_first_submitted>August 6, 2003</study_first_submitted>
  <study_first_submitted_qc>August 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2003</study_first_posted>
  <last_update_submitted>April 30, 2013</last_update_submitted>
  <last_update_submitted_qc>April 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2013</last_update_posted>
  <keyword>essential thrombocythemia</keyword>
  <keyword>polycythemia vera</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>chronic idiopathic myelofibrosis</keyword>
  <keyword>atypical chronic myeloid leukemia</keyword>
  <keyword>myelodysplastic/myeloproliferative disease, unclassifiable</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

